List of Microbiome Companies with Phase 1 Active Clinical Trial - 22

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle.

BGI was founded in 1999 as a research organization to support the Human Genome Project. Over the years, BGI’s in-house research has contributed to the development of the field of Genomics in significant ways, as evidenced by a wealth of peer-reviewed publications in prestigious scientific journals. Today, BGI is actively participating in the fields of Cancer Research, Bio-sustainability and Personalized Medicine through a global network of collaborators. BGI Genomics is the world’s leading provider of genomic and proteomic services, now serving customers in more than 66 countries. We provide academic institutions, pharmaceutical companies, health care providers and other organizations with integrated genomic and proteomic services and solutions across a broad range of applications spanning basic and translational research, drug discovery, agriculture and health care. To provide these services, we operate a large network of service Laboratories in China, Hong Kong, the US and Europe. Our customers benefit from the highest level of sequencing experience in the world to support their research and drug discovery projects. Our service laboratories operate under strict internationally recognized quality systems, such as those from CAP and ISO. More recently, BGI developed and launched its own DNBseq™ sequencing technology, based on DNA Nanoball sequencing technology that was invented in our Complete Genomics research facility in Silicon Valley, California. Scientists around the world now rely on DNBseq NGS services for the highest quality data at the lowest cost.

BIOHM optimizes digestive health by combining good bacteria, good fungi and enzymes to break down digestive plaque, allowing for total gut balance. This allows BIOHM's 30 billion live active cultures to maintain, support, and promote the balance of the total microbiome in the digestive system.

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

Carbiotix is an award-winning biotechnology company pioneering the onsite upcycling of plant-based side-streams. Carbiotix mission is to improve the health of people by increasing the consumption of prebiotics and other active ingredients from upcycled side-streams. Carbiotix offers one core service today called NutraCycle, an on-site upcycling and fortification service allowing food & beverage, ingredient, and feed producers to turn plant-based products into healthier, more profitable, and sustainable products.

Freya™ is a clinical-stage company taking an innovative approach to women’s health, with microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of reproductive system diseases uniquely afflicting women.

KoBioLabs is recognized for its international level of microbiome therapeutic technologies. In particular, our researchers have a distinctive position in the microbiology field globally with their presence in the ongoing International Human Microbiome Consortium [IHMC].

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers

Founded in 1895, Nexira is a family owned company who built its reputation as the world leader in acacia gum. Today Nexira is a global leader in natural ingredients and botanical extracts for food, nutrition, and dietary supplements. Our ingredients are perfectly suitable for the formulation of clean label products. Nexira manufactures in France a wide range of natural ingredients with recognized health benefits, such as Fibregum™ an all-natural, organic and GMO-free source of soluble dietary fiber. Nexira's portfolio for food industry includes a large range of branded natural acacia gum ingredients with exceptional functional properties (Emulsifiers & stabilizers, coating agents, texturizers, encapsulating agents…). Nexira's portfolio for supplement industry includes premium nutraceuticals, strongly supported with scientific & marketing supports, for digestive health, weight management, sports nutrition, joint health and men & women’s health.

Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to receive FDA authorization to test a live bacterial therapeutic, and is a pioneer in the field of LBPs. Our proprietary approach identifies differences between healthy and disease-related microbiomes, and leverages beneficial microbes to treat problematic disruptions or ‘dysbioses’. Osel’s approach of repopulating the microbiome with beneficial bacteria helps restore healthy and protective microbiomes. The primary focus of our work is women’s health, with indications including recurrent urinary tract infections and bacterial vaginosis. Our secondary focus is disorders of the gastrointestinal tract. Our product pipeline is demonstrating exciting therapeutic potential, with two clinical stage products and ongoing clinical trials.

Welcome to Ostia Sciences, a premier microbiome solutions company that specializes in discovering novel bacterial metabolites with antibacterial, antibiofilm, and immunomodulation activities. Our goal is to isolate beneficial microbes from the human oral microbiome, human breast milk, and fermented food, which are known to be rich sources of ribosomally synthesized and post-translationally modified peptides (RiPPs) and natural products with a range of biological activities.

Persephone is pioneering the use of synthetic biology for microbial products that impact patient and infant health. We are building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler PhD, and Steve Van Dien PhD.

Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process, and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally.

Probiotical is an Italian family-owned company specialized since 1985 in probiotics manufacture, from the raw material to the finished products, with very high quality, guaranteed stability and scientifically backed strains. We are driving innovation in a variety of functionalities and technologies. We offer our customers wide opportunities of customization and range extensions for probiotic blends and finished products ready-to-market, either under Probiotical's brand or in private label.

Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.

science backed probiotics, prebiotics & bioactive botanicals for targeted restoration res makes physician developed & physician recommended supplements creator of the world's first respiratory probiotic resB!

Rise Therapeutics is developing targeted immunological-based biologics using a unique and proprietary oral delivery platform. The company develops unique, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity and cancer.

Solarea Bio is a clinical-stage biotechnology company in Cambridge, MA developing plant-based microbial solutions to some of the world's largest health problems. Solarea was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health. The Solarea breakthrough came from the combined efforts of the company's co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods, and their applications in inflammatory processes including the gut-musculoskeletal axis. Using powerful genomic and bioinformatic tools, Solarea is mining its novel microbial strain collection to identify synergistic combinations of microbes and prebiotic plant fibers to develop solutions for patients suffering from inflammatory processes.

From discovery to scale, Verb Biotics applies science, technology, and intentional development to deliver microbiome health solutions. Verb Biotics is a business-to-business ingredient supplier of pro, post, and synbiotics for food, beverage, and dietary supplement brands.

Viomeanalyzes your microbiome and uses artificial intelligence to process the results and provide dietary advice.

Winclove Probiotics, quality of life with probiotics Since 1987, Winclove Probiotics has specialized in the development and production of probiotics. We work with passionate business partners, leading universities, various research institutes and university hospitals around the world to develop effective indication-specific probiotics. Aiming for long-lasting, sustainable and strategic partnerships, we not only offer innovative, high-quality and competitive probiotic solutions but also share our scientific knowledge as much as possible. At Winclove Probiotics, commitment, drive and optimism are important. Our Great Place to Work certification also shows that we have a company culture of humanity, diversity and trust. Since 2020, we have been part of the B Corp community, joining forces with like-minded companies to protect our planet and contribute to a sustainable economy. Together, we are using ‘business as a force for good'. -- Winclove Probiotics, kwaliteit van leven met probiotica Sinds 1987 is Winclove Probiotics gespecialiseerd in de ontwikkeling en productie van probiotica. Wij werken met gedreven businesspartners, vooraanstaande universiteiten, uiteenlopende onderzoeksinstituten en (universitaire) ziekenhuizen wereldwijd om effectieve indicatiespecifieke probiotica te ontwikkelen. We streven naar langdurige, duurzame en strategische partnerships waarbij wij niet uitsluitend innovatieve, hoogwaardige en concurrerende probiotica-oplossingen bieden, maar ook zoveel mogelijk onze wetenschappelijke kennis delen. Bij Winclove Probiotics zijn betrokkenheid, gedrevenheid en optimisme belangrijk. Ons Great Place to Work-certificaat toont tevens aan dat we een bedrijfscultuur van menselijkheid, diversiteit en vertrouwen hebben. Sinds 2020 zijn we onderdeel van de B Corp-community en bundelen we met gelijkgestemde bedrijven de krachten om onze planeet te beschermen en bij te dragen aan een duurzame economie. Samen gebruiken we ‘business as a force for good.'

Yakult is the world's leading probiotic beverage created in Japan in 1935. It is produced by Yakult Honsha Co., Ltd - the world's pioneer in probiotics. Today, Yakult is sold in more than 30 countries and regions around the world. Our company's portfolio includes a range of consumer, cosmetic and pharmaceutical products. For additional company information, please visit www.yakult.co.jp/english/. Science and research are the basis of our business. We have institutes in both Japan and Europe that are committed to discovering the endless applications for probiotics as well as the use of intestinal bacteria in human health globally. For more information about our science institutes, please visit www.yakult.co.jp/institute. Bringing Yakult to America is just one more step towards fulfilling Yakult's mission: to contribute to the health and happiness of every person around the world through the pursuit of excellence in life sciences and the study of microorganisms. We hope to achieve this goal while providing education to people about healthier living, developing community programs where we do business, and collaborating with medical doctors, dietitians and researchers. Yakult U.S.A. Inc. is a subsidiary of Yakult Honsha Co., Ltd. and is headquartered in Fountain Valley, CA. It supports Yakult's business in the United States and Canada. To contact our offices please email yakult@yakultusa.com.